CY1110238T1 - Εμβολιο ιου ηπατιτιδας c - Google Patents

Εμβολιο ιου ηπατιτιδας c

Info

Publication number
CY1110238T1
CY1110238T1 CY20101100687T CY101100687T CY1110238T1 CY 1110238 T1 CY1110238 T1 CY 1110238T1 CY 20101100687 T CY20101100687 T CY 20101100687T CY 101100687 T CY101100687 T CY 101100687T CY 1110238 T1 CY1110238 T1 CY 1110238T1
Authority
CY
Cyprus
Prior art keywords
nucleic acid
vaccine
virus
hcv
dependent
Prior art date
Application number
CY20101100687T
Other languages
English (en)
Inventor
Emilio A Emini
David C Kaslow
Andrew J Bett
John W Shiver
Alfredo Nicosia
Armin Lahm
Alessandra Luzzago
Riccardo Cortese
Stefano Colloca
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02773740A external-priority patent/EP1436397B1/en
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of CY1110238T1 publication Critical patent/CY1110238T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρουσιάζει Ad6 φορείς και ένα νουκλεϊνικό οξύ το οποίο κωδικοποιεί ένα Met-NS3-NS4A-NS4B-NS5A-NS5B πολυπεπτίδιο το οποίο περιέχει μια αδρανή NS5B RNA-εξαρτώμενη περιοχή πολυμεράσης. Το νουκλεϊνικό οξύ είναι ιδιαίτερα χρήσιμο ως ένα συστατικό ενός εμβολίου αδενοφορέα ή DNA πλασμιδίου το οποίο παρέχει ένα πλατύ εύρος αντιγόνων για πρόκληση μιας HCV ειδικής κυτταροεξαρτώμενης άνοσης (CMI) απόκρισης ενάντια σε HCV.
CY20101100687T 2001-10-11 2010-07-21 Εμβολιο ιου ηπατιτιδας c CY1110238T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32865501P 2001-10-11 2001-10-11
US36377402P 2002-03-13 2002-03-13
EP02773740A EP1436397B1 (en) 2001-10-11 2002-10-10 Hepatitis c virus vaccine

Publications (1)

Publication Number Publication Date
CY1110238T1 true CY1110238T1 (el) 2015-01-14

Family

ID=26986462

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100687T CY1110238T1 (el) 2001-10-11 2010-07-21 Εμβολιο ιου ηπατιτιδας c

Country Status (7)

Country Link
EP (1) EP2172552A3 (el)
JP (1) JP4479973B2 (el)
CN (2) CN101988071B (el)
CY (1) CY1110238T1 (el)
DE (1) DE60236364D1 (el)
ES (1) ES2344253T3 (el)
PT (1) PT1436397E (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011040535A1 (ja) 2009-09-30 2011-04-07 東レ株式会社 Ｃ型肝炎ウイルスワクチン組成物
EP2516664B1 (en) * 2009-12-21 2015-07-22 Pharmathene Inc. Recombinant butyrylcholinesterases and truncates thereof
SG11202003609VA (en) * 2017-10-25 2020-05-28 Nouscom Ag Eukaryotic cell line
AU2021218411A1 (en) * 2020-02-13 2022-10-06 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5266313A (en) 1987-02-03 1993-11-30 The United States Of America As Represented By The Department Of Health And Human Services Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5863542A (en) 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
CN1189855A (zh) * 1995-06-29 1998-08-05 史密斯克莱·比奇曼生物公司 抗丙型肝炎病毒的疫苗
EP1009763A4 (en) * 1996-06-11 2002-08-07 Merck & Co Inc SYNTHETIC GENES OF HEPATITIS C
DE69835761T2 (de) 1997-04-03 2007-09-13 Electrofect As. Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel
NZ500656A (en) * 1997-05-12 2001-11-30 Tno Vector containing a nucleic acid insertion expressing a hybrid polypeptide with a protease inhibitor domain and a receptor binding domain
JP2002511396A (ja) 1998-04-14 2002-04-16 メルク エンド カムパニー インコーポレーテッド ポリヌクレオチド製剤の無針投与
WO1999057296A1 (en) * 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
US6156588A (en) 1998-06-23 2000-12-05 Vlsi Technology, Inc. Method of forming anti-fuse structure
JP2002523054A (ja) * 1998-08-24 2002-07-30 ジェンザイム・コーポレイション ポリマーにより修飾されたアデノウイルスのカチオン性複合体
US6562346B1 (en) 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
CN1254719A (zh) * 1999-11-19 2000-05-31 钱其军 一种缺陷型腺病毒及其构建方法
CA2390082C (en) 1999-11-24 2010-06-29 Chiron Corporation Novel hcv non-structural polypeptide
DK1436397T3 (da) * 2001-10-11 2010-08-09 Merck Sharp & Dohme Hepatitis C virus vaccine

Also Published As

Publication number Publication date
CN101988071B (zh) 2016-07-06
CN1880457A (zh) 2006-12-20
ES2344253T3 (es) 2010-08-23
CN1880457B (zh) 2010-05-26
JP2009183295A (ja) 2009-08-20
EP2172552A3 (en) 2010-07-21
CN101988071A (zh) 2011-03-23
DE60236364D1 (en) 2010-06-24
EP2172552A2 (en) 2010-04-07
PT1436397E (pt) 2010-07-15
JP4479973B2 (ja) 2010-06-09

Similar Documents

Publication Publication Date Title
ATE467680T1 (de) Hepatitis-c-virus-impfstoff
ATE297757T1 (de) Chimäre impfstoffe gegen flaviviren
DK1026262T3 (da) Oligonukleotidprimere til effektiv detektering af hepatitis C-virus (HCV) og fremgangsmåder til anvendelse deraf
CY1110238T1 (el) Εμβολιο ιου ηπατιτιδας c
DK1542732T3 (da) Fusionsproteiner af Mycobacterium tuberculosis
DK0698216T4 (da) Fremgangsmåder til typebestemmelse af hepatitis-C-virus og anvendte reagenser heri
DE68903165D1 (de) Rns des genoms des non-a, non-b-hepatitisvirus und antigenisches virales protein.
DK1450856T3 (da) Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
SE9004010D0 (sv) Viralt medel
DK0783321T3 (da) VR-2332 viral nucleotidsekvens og fremgangsmåder til anvendelse
DK1375670T3 (da) Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
RU2005118419A (ru) Вакцина против вируса лихорадки западного нила
DK1198570T3 (da) Monomert protein af TGF-Beta-familien
ATE362538T1 (de) Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen
CY1109023T1 (el) Gm-αρνητικα μεταλλαγματα ehv
HK1053144A1 (en) Hepatitis b virus dna polymerase and surface antigen variants and methods of using same
ATE442858T1 (de) Nukleinsäureadjuvantien
BR0112020A (pt) Partìculas tipo vìrus de bvdv
ATE115964T1 (de) Non-a non-b sequenzen.
DK1200132T4 (da) Nucleinsyre-og aminosyresekvenser af infektiøs lakseanæmivirus og deres anvendelse som vacciner
CY1105473T1 (el) Ολιγονουκλεοτιδικα εκκινητηρια μορια για την αποτελεσματικη αντιστροφη μεταγραφη του rna του ιου της ηπατιτιδας c (hcn) και μεθοδοι για τη χρηση τους
CY1110861T1 (el) Μορια νουκλεϊνικων οξεων toy hdv, θραυσματα αυτων και εφαρμογες αυτων
DE60229966D1 (de) Diabetesmodell
DE69937258D1 (de) Genetische impstoffe mit adjuvans